A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy

Inclusion Criteria: * women with a recent diagnosis of T1 or T2 non-invasive breast cancer by large core needle or excisional biopsy * confirmation that tissue was processed in methods acceptable to protocol and sufficient tissue remains post-diagnostic analyses to perform research assessments * reexcision planned within 10 days to 6 weeks from study start * if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision Exclusion Criteria: * no hormone replacement therapy within the 90 days prior to biopsy * if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision * no evidence of metastatic malignancy of any kind * no history of asthma, allergy ASA, NSAIDS, celecoxib or other COX-2 inhibitors for a chronic non-oncological condition with the excision of low dose ASA (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study. * no celecoxib or rofecoxib use within one month of biopsy * no history of gastrointestinal ulcer or ulcerative colitis requiring treatment * no current anticoagulants * no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study * no aromatase inhibitor in the six months prior to participation * no concomitant lithium * no known significant bleeding disorder